Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Culturally Enhanced Augmented Realities (CULTAR)

Framework: FP7 — Cooperation
Programme: Information and Communication Technologies
Destination: ICT for Learning and Access to Cultural Resources
Action type: Collaborative project
Countries involved: Finland,Austria,Denmark,Italy
Call:  (FP7-ICT-2011-9, 2011)
Start date: 2013-01-01
End date: 2015-12-31
Duration (months): 36.0
Total project cost (EUR): 4364255.0
EU funding (EUR): 3400000.0
Participants: 7
Project status: CLOSED

CultAR will provide a mobile platform that 1) actively increases users’ awareness of their cultural surroundings with advanced, adaptable and personalized interfaces, 2) increase users’ social engagement with culture via a leap in social media technologies and contextual inference methods. To reach these goals, CultAR will advance the State of the Art in mobile 3D, augmented reality and tactile technologies, combining them into a completely new mobile experience interface. The CultAR platform achieves personalised and engaging digital cultural experiences through enhanced representation, hybrid space mediation, social engagement and awareness. Adaptability and context awareness will be enhanced through dynamic 3D models of urban environments with an ability to control all aspects of the representation, including dynamic content such as the presence of other users (real and virtual) and user created Culture Ghosts, applying various emphasis methods that draw the attention of the user to potentially interesting cultural content. A user-centric approach is applied throughout the development. During the first phase, scenarios are designed together with cultural stakeholders. Application design is iterative, where end user input is directly taken into the development loop. Cultural stakeholders will provide content and expert users for CultAR. Advances in technology are verified and analyzed not just by technical benchmarking, but with both specialist analysis and on-location field experiments in Padua, Italy and Aalborg, Denmark. Methodology in measuring user experiences is developed with thorough monitoring using eye trackers, physiological sensors, gesture tracking and gesture recognition in pursue of inferring emotional states quantitatively.

Keywords: markerless augmented reality,mobile 3d maps,tactile systems,personalized and digital cultural experience,on-site trials
Support Action for a Targeted Intelligent Autonomous Robotics Contest: The European Roboathlon (EURATHLON)

Framework: FP7 — Cooperation
Programme: Information and Communication Technologies
Destination: Cognitive Systems and Robotics
Action type: Coordination and support actions
Countries involved: United Kingdom,Germany,Finland,United Kingdom,Spain,Belgium,Spain
Call:  (FP7-ICT-2011-9, 2011)
Start date: 2013-01-01
End date: 2015-12-31
Duration (months): 36.0
Total project cost (EUR): 1745819.0
EU funding (EUR): 1649996.0
Participants: 8
Project status: CLOSED

EURATHLON is a new outdoor robotics competition, which will invite teams to test the intelligence and autonomy of their robots in realistic mock emergency-response scenarios. Inspired by the 2011 Fukushima accident the EURATHLON competition will require a team of land, underwater and flying robots to work together to survey the scene, collect environmental data, and identify critical hazards. Leading up to this ‘grand challenge’ in 2015, will be directly related land and underwater robot competitions in 2013 and 2014, respectively. The EURATHLON competitions will be supported by annual workshops for competitors. In parallel there will be an open process of developing benchmarks to allow comparison of different robots in the EURATHLON competitions. Linked public engagement activities will connect EURATHLON with robotics research, industry and emergency services, as well as the general public. Attendance of spectators will be welcomed, and we hope that EURATHLON events will attract considerable press and media attention. By targeting a specific and urgent need - intelligent robots for disaster-response - EURATHLON will provide European robotics with a platform for challenging, extending and showcasing European cognitive robotics technologies.

Keywords: intelligent autonomous robots,unmanned ground,underwater and air vehicles (ugvs,uuvs and uavs),robotics competitions,smart robots for disaster response,multi-robot cooperation,benchmarks
AN INNOVATIVE CAUSAL THERAPY FOR ALLERGY: SAFE AND RAPID INDUCTION OF AN ANTI-INFLAMMATORY IMMUNE RESPONSE USING A MUTANT HYPOALLERGEN AND VITAMIN D3 (BM4SIT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,Austria,Netherlands,Austria,Denmark,Germany,Poland,Finland
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-02-01
End date: 2019-01-31
Duration (months): 60.0
Total project cost (EUR): 7807110.4
EU funding (EUR): 5996408.0
Participants: 10
Project status: CLOSED

Allergy is the most prevalent chronic inflammatory disease, having great socio-economic impact. Chronic lifelong dependency on symptomatic drugs is an expensive reality for the vast majority of allergy sufferers. Allergen-specific immunotherapy is the only causal and effective treatment targeting the underlying immune mechanism in a more cost-effective way. Yet, long treatment duration and risk of anaphylactic side-effects have prevented this treatment from becoming the first choice. BM4SIT aims at providing an escape from its current niche position by making the treatment safer, more effective and patient friendlier, i.e. developing a therapy with negligible side-effects but improved efficacy, achieved by less injections. The concept of BM4SIT is based on two innovations: replacing current natural allergen extracts by mutated recombinant allergens having been designed to be hypo-allergenic but hyper-immunogenic, and adding an adjuvant to support rapid and effective induction of an anti-inflammatory immune response. The allergen derivative chosen to bring this concept from bench to bedside is BM41, a mutant of the culprit allergen of birch pollen allergy, Bet v 1. Pre-clinical data have demonstrated strongly reduced allergenicity, significantly increased immunogenicity and efficacy in a mouse model for birch pollen allergy. The selected adjuvant is vitamin D3, which has been shown to promote active suppression of inflammation, both in vitro and in a mouse model. The product-focused, IP-protected consortium of BM4SIT will test the immunological and clinical added value of vitamin D3in combination with a current product in a randomized DBPC trial. First-in-man safety of BM41 will be evaluated against placebo, using a current product as comparator. Preliminary efficacy data will be obtained using surrogate in vitro serological and cellular tests.

Keywords: chronic inflammation/allergy/birch/immunotherapy/causal therapy/hypoallergenic mutant/strong immunogen/novel adjuvant/vitamind3/increased safety/rapid onset efficacy/regulatory t-cells/il-10/igg4/iga.
Testing and validation of bispecific antibody combinations targeting treatment-resistant cancer stem cells using organoid-based screening tools: a new drug discovery paradigm (SUPPRESSTEM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Horizontal topics for collaborative projects relevant for the whole of theme health
Action type: Collaborative project
Countries involved: Netherlands,Spain,United Kingdom,Netherlands,Netherlands
Call:  (FP7-HEALTH-2013-INNOVATION-2, 2013)
Start date: 2013-06-01
End date: 2016-11-30
Duration (months): 42.0
Total project cost (EUR): 7756658.4
EU funding (EUR): 5953319.0
Participants: 5
Project status: CLOSED

Colorectal cancer (CRC) was diagnosed in 1.23 million people worldwide (EU 333,000) in 2008 and 608,000 (EU 148,000) died of the disease. While some new treatments have been advanced in CRC many have failed clinical testing; metastatic CRC is still largely incurable. In CRC, Cancer Stem Cells (CSC) are responsible for tumour progression and resistant to standard chemotherapies. The Wnt signal transduction cascade controls normal colon physiology but also CSC maintenance. Deregulation of Wnt and other mitogenic pathways results in formation of aggressive tumours with metastatic potential. Novel combinatorial drugs targeting CSCs are required to address signalling redundancy and subvert resistance and escape mechanisms. However to test them effectively better drug screening tools must be developed. The high failure rate in cancer drug research has been linked to the poor predictive capacity of drug screening models for cancer and the inability to select the right patients for treatment. In SUPPRESSTEM, novel antibody-based therapeutics will be designed to modulate the Wnt pathway externally in combination with mitogenic receptors resulting in specific inhibition of CSCs with minimal toxicity on healthy tissue. The likelihood of clinically translating these goals will be enhanced because testing will be performed on relevant human patient material (both tumour and normal) using organoid technology and novel imaging readouts. In depth analysis of the phenotype of responsive organoids (patient material) will be used to identify a lead product. Successful execution of SUPPRESSTEM will provide an innovative drug product and drug screening tool ready for clinical validation that ultimately will increase the life expectancy and quality of cancer patients. Funding of SUPPRESSTEM will enable three research-focused SME’s to establish an innovative drug discovery paradigm with broad application in the cancer drug development.

Keywords: cancer stem cells bispecific antibodies combination treatment colorectal cancer patient stratification wnt signalling pathway organoids high-throughput screening personalised medicine imaging
European Gender Medicine Network (EUGENMED)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Germany,Netherlands,Ireland
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2015-09-30
Duration (months): 24.0
Total project cost (EUR): 538282.0
EU funding (EUR): 496000.0
Participants: 3
Project status: CLOSED

Research addressing sex and gender (S&G) in biomedical sciences and health care research is emerging as a novel and highly promising field. Interaction of S&G related mechanisms leads to different manifestation of frequent diseases such as infarction, heart failure, diabetes, rheumatic disease, etc. in women and men. Research in this area will lead to novel, better targeted and therefore more efficient treatment strategies than the previous global approaches and will increase prevention and healthy life expectancy .We suggest to produce an innovative roadmap for implementation of S&G in biomedicine and health research. To achieve these objectives we will develop EUGENMED into an open European Gender Health Network that includes all stakeholders and decision makers. We will organize 6 meetings with all stakeholders that will result in recommendations, guidelines and teaching materials for the implementation of S&G research for target audiences, doctors, medical associations, teachers, students, researchers, industry, health policy makers, funding agencies and politicians. Materials shall be disseminated through a European Gender Health Portal. The aim is to create a truly multi- sectorial sourcing of knowledge, a key factor for building consensus and helping close the participatory governance gaps. Inclusiveness, openness and transparency will be key principles. Dissemination of S&G strategies to the next generation of medical interventions and therapies shall improve the health of European citizens. Project outcomes will be fed into relevant policy processes at the EU level e.g. Horizon 20/20. EUGENMED will lead to significant innovations by introducing S&G into medical practice and research and improve European citizens’ health and Europe’s standing in biomedicine. Keywords: Gender Medicine, biomedicine, health care research, pharmacology

Keywords: gender medicine,clinical medicine,biomedical research,drug development,regulations,sustainability,added value
Global initiative on gene-environment interaction on diabetes/obesity risk (INTERCONNECT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: United Kingdom,Austria,Finland,United States,Germany,Netherlands,Ireland,Netherlands,Germany,Canada
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2017-09-30
Duration (months): 48.0
Total project cost (EUR): 2338929.66
EU funding (EUR): 1998314.0
Participants: 12
Project status: CLOSED

The overall goal of InterConnect is to establish a global network that will facilitate the co-ordination of population research on the interaction between genetic and environmental factors in the aetiology of obesity and diabetes. We aim to establish mechanisms for identification and classification of studies and the data that they hold and create a forum for harmonization of methods as a foundation for optimizing the use of existing data for the study of gene-environment interaction. We aim to establish a funders’ forum and a forum for stakeholders and bring these groups together with subject-specific researchers and methodologists to create an appropriately governed framework for sharing existing data, harmonizing the addition of new data and planning new studies. With the involvement of strong funders’ and stakeholders’ fora in InterConnect from the outset, the project will provide a network to link, co-ordinate and eventually integrate EU funded research activities with those in other continents. InterConnect will provide a forum for exchange of information and best practice between projects. This will be relevant both to the research community and also the funders. The engagement of stakeholders and our dissemination programme will ensure that the knowledge that is ultimately gained through collaborative work in this network will be translated into policy, social and economic benefits. Through its work on an ethical and legal framework, InterConnect will create a sustainable framework that will facilitate data sharing that is transparent and dynamic.

Keywords: diabetes,obesity,genetics,environment,lifestyle,interaction,population science
European Asthma Research and Innovation Partnership (EARIP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: United Kingdom,Sweden,Belgium,Netherlands,Greece,United Kingdom,Switzerland,Poland,Spain,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2016-08-31
Duration (months): 36.0
Total project cost (EUR): 778764.2
EU funding (EUR): 500000.0
Participants: 13
Project status: CLOSED

Europe has 30 million people with asthma, whose treatment costs about €20 bn annually. Productivity lost through poor asthma control in Europe is estimated to be €9.8 bn per year. By 2020 approximately 120,000 people in Europe will die from asthma attacks, and 4 million hospitalisations will be needed for the most severely affected. The Objectives of EARIP (European Asthma Research and Innovation Partnership) include to: • reduce the annual level of deaths by 25% within 10 years and 50% within 20 years, and hospitalisations by 50% • identify more effective mechanisms to discover, develop and prioritise biological targets to helping pharmaceutical companies reduce asthma attacks and hospital admissions in asthma of varying severity and mechanistic sub-type • develop new systems, models and tools for the phenotypic stratification of asthma, and determine priority needs of sub-groups • identify innovations needed in health and care systems to put individual patients at the heart of asthma management/treatment, and improve outcomes with better diagnostic and patient self-management plans • review research gaps in treatment of asthma identified at national and international levels, and rank in priority order • identify and internationally ratify a list of research objectives of greatest potential added value in the treatment and management of asthma and produce a Roadmap setting out priorities for the research and innovations needed • address the fragmentation of research approaches and healthcare systems in the management of asthma that has resulted in European countries being 14 of the world's worst 20 for prevalence of asthma in adults, and bring together European stakeholders who will together to address specific Objectives, and review how best to establish a European Innovation Partnership, its Vision, Strategic Priorities, Priority Actions, representative core membership, organisational and governance structure, and requirements for wider interactions

Keywords: asthma death,asthma biological target,asthma phenotype,health system innovation,patient self-management,asthma stakeholder,asthma research gap
Anti-Parasitic Drug Discovery in Epigenetics (A-PARADDISE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,France,Germany,Brazil,Germany,Sweden,Australia,Italy,United Kingdom,Sweden
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-02-01
End date: 2017-01-31
Duration (months): 36.0
Total project cost (EUR): 8638614.0
EU funding (EUR): 5999991.0
Participants: 16
Project status: CLOSED

This proposal builds on the proven methodology developed in the SEtTReND FP7 project to develop inhibitors of schistosome HME as lead compounds for new drugs. We will employ a target-based strategy for the development of novel drug leads against schistosomiasis, leishmaniasis, Chagas disease and malaria by targeting histone modifying enzymes (HME), in particular those involved in acetylation/deacetylation and methylation/demethylation. The principal objectives of A-PARADDISE are: - The identification of HMEs from Leishmania sp. and Trypanosoma cruzi and the molecular characterization and functional characterization of selected potential targets, - Phenotypic screening of Leishmania, T. cruzi, S. mansoni and P. falciparum using HME class inhibitors, inhibitors developed specifically against S. mansoni and P. falciparum HMEs. This will permit us to obtain a comprehensive view of inhibitor classes and chemical scaffolds of interest, - Production of recombinant Leishmania and T. cruzi HME proteins, structural studies. Selected, validated target enzymes will be produced, crystallized and analysed by X-ray diffraction. Assays will be optimized to permit testing of inhibitors, - High-throughput and structure-based (in silico) screening of selected HMEs. Inhibitors selected will be further screened by phenotypic assays on the parasites in vitro, - Optimisation of inhibitor structures by chemical synthesis based on molecular modelling studies (inhibitors of all origins), - Transcriptomic analysis of drug-treated parasites to verify target specificity and mechanism of action (all parasites), - Pharmacological and toxicological studies (in vitro and in vivo) of selected inhibitors, in vivo testing of compounds in parasite-infected mice. The overall objective of the A-PARADDISE project is to develop optimized epigenetic inhibitors for further testing and optimisation as drug candidates against the four parasites studied.

Keywords: parasite,schistosomiasis,leishmaniasis,chagas disease,malaria,epigenetics,drug,histone modifying enzymes,histone deacetylase
Towards a Sustainable and Affordable Healthcare (WE-CARE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Sweden,United Kingdom,Luxembourg,Netherlands,Israel,Belgium,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2015-08-31
Duration (months): 24.0
Total project cost (EUR): 566952.94
EU funding (EUR): 499690.0
Participants: 7
Project status: CLOSED

The aim of this action is to prepare the future for health research and innovation to contribute significantly towards a sustainable and affordable healthcare. EU-wide there is a clear and present need to contain healthcare costs to keep the healthcare affordable to all EU citizens. In many EU member states healthcare budgets are overstretched and in some states the growth of these budgets seem even out of control. The societal and economic impact of this emerging trend is significant, jeopardizing the affordability of healthcare to all EU-citizens. The EU R&D–program could act as an important catalyst for change. Insights are needed on important cost drivers and on the influence of institutional settings. Innovations in technology and methods, which can contain future costs, should be developed and utilized. The challenge is to do so while maintaining or even improving the quality of care. EU-key players need to come together to discuss this challenge. In collaboration a strategy plan for the development of this research area need to be defined to facilitate and realize the needed breakthrough. They should define a roadmap to: 1) Advice on shifts in accents towards cost containment in the present HEALTH-R&D program and other initiatives and 2) Develop a supplementary R&D – agenda to fill in the present R&D gaps and needs for a breakthrough in cost containment. This roadmap will contribute to keep the present and future EU HEALTH R&D program relevant to all EU-citizens. WE-CARE presents a multi-disciplinary approach since financial, technical, economic, cultural and ethical aspects are strongly intertwined. The consortium will seek cooperation with relevant EU initiatives to gain as much impact without developing new, solitary actions. Though the aim of this action is to develop a roadmap, an important spin-off is the creation of a commitment on a shared responsibility amongst all EU-key players to keep the healthcare affordable to all EU-citizens.

Keywords: healthcare budget,cost containment,multi-disciplinary,medical innovation,quality of care,sustainable healthcare,patient,person centered care,institutional change,efficiency of care